Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The investigators' long-term goal is to improve the survival of patients with pancreatic
cancer by enhancing the efficacy of gemcitabine-radiation by adding the Wee1 inhibitor
MK-1775.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center